25 completed, 3 unknown, 2 not yet recruiting, 1 terminated. 32 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 32 | Completed 25, Unknown 3, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Unknown 1 |
Follow Placebo capsule: new trials by email Literature Review of Placebo capsule trials Research Report on Placebo capsule
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Dexamethasone on Short Term Patient Response: IV vs Oral Administration Dexamethasone IV injection, Dexamethasone Capsule, Placebo IV administration - Post Operative Pain, Acute, Periodontitis | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 40 | 2026-10-01 | 2026-09-21 |
| A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of KR23248 Capsules in Healthy Adult Subjects KR23248, Matching Placebo - Schizophrenia | Phase 1 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 66 | 2026-05-19 | 2026-05-15 |
| Progesterone and Muscle Protein Synthesis in Premenopausal Women (MP4-MPS) Micronized progesterone (oral capsules), placebo capsule - Healthy Volunteers, Female | Phase 1 | Completed | McMaster University | 20 | 2026-01-01 | 2026-06-17 |
| Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule - Eosinophilic Esophagitis | Phase 1 | Completed | AQILION AB | 9 | 2025-06-13 | 2026-06-01 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules CS32582 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 112 | 2024-03-28 | 2024-12-03 |
| A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis Microbiota suspension, Microbiota capsule, Placebo suspension - Ulcerative Colitis | Phase 1 | Withdrawn | Ferring Pharmaceuticals | 2024-03-12 | 2024-10-18 | |
| A Clinical Trial of CS12192 in Healthy Subjects CS12192 capsule, Placebo capsule - Healthy | Phase 1 | Completed | Chipscreen Biosciences, Ltd. | 108 | 2023-07-20 | 2024-02-07 |
| Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007) Nicotine patch, MK-4334, Placebo patch - Cognitive Impairment Associated With Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 38 | 2022-04-27 | 2024-11-29 |
| Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients FADA (active fraction of Ficus septica leaf) 800 mg/day, FADA (active fraction of Ficus septica leaf) 2000 mg/day, Placebo capsule - Breast Cancer Stage IV | Phase 1 / Phase 2 | Unknown | Gadjah Mada University | 324 | 2021-10-25 | 2024-02-28 |
| A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics In Healthy Adult Human Subjects ZY19489 Capsule, Placebo Capsule - Malaria | Phase 1 | Completed | Zydus Lifesciences Limited | 24 | 2021-08-25 | 2022-07-11 |
| Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study Placebo capsule, Dronabinol 7.5 milligram oral capsule - Posttraumatic Stress Disorder | Phase 1 | Completed | Wayne State University | 102 | 2021-04-15 | 2025-07-11 |
| Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects CKD-508 Capsule, Placebo Capsule, CKD-508 Tablet - Healthy Subjects | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 88 | 2020-07-06 | 2024-02-15 |
| The Study of a Selective 5-ht6 Receptor Antagonist, HEC30654AcOH,in Healthy Subjects HEC30654AcOH capsule, Placebo capsule - Healthy | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 43 | 2018-11-21 | 2026-05-01 |
| Omega-3 PUFA for Treatment of Patients With Idiopathic Oligoasthenoteratospermia Omega 3 fatty acid, Placebo oral capsule - Male Infertility Due to Hypospermatogenesis | Phase 1 | Unknown | Jinling Hospital, China | 30 | 2017-11-08 | 2021-09-16 |
| A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects GSK2982772 capsule, Placebo capsule - Autoimmune Diseases | Phase 1 | Completed | GlaxoSmithKline | 62 | 2017-10-11 | 2023-10-10 |
| Midodrine Hydrochloride in Early Sepsis Midodrine Hydrochloride 10 milligrams, Placebo capsule - Sepsis, Blood Pressure | Phase 1 | Completed | Mayo Clinic | 33 | 2017-08-30 | 2021-02-05 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers SKI-O-703 capsule, Placebo capsule - Arthritis, Rheumatoid | Phase 1 | Completed | Oscotec Inc. | 24 | 2016-09-22 | 2017-10-20 |
| Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients N-Methanocarbathymidine, Placebo Capsule - Toxicity | Phase 1 | Unknown | N&N Pharmaceuticals Inc. | 28 | 2016-04-01 | 2016-09-22 |
| Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers SKI-O-703 capsule, Placebo capsule - Rheumatoid Arthritis | Phase 1 | Completed | Oscotec Inc. | 48 | 2015-09-01 | 2018-02-28 |
| A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects GSK2982772 solution, GSK2982772 capsule, Placebo solution - Inflammatory Bowel Diseases | Phase 1 | Completed | GlaxoSmithKline | 79 | 2015-01-06 | 2017-05-09 |
Showing 20 of 32. Sign in to see all of them.
Arthritis, Rheumatoid (2) · Schizophrenia (2) · Attention Deficit Disorder with Hyperactivity (1) · Autoimmune Diseases (1) · Breast Neoplasms (1) · Bronchiectasis (1) · Colitis, Ulcerative (1) · Eosinophilic Esophagitis (1) · Fabry Disease (1) · Infertility, Male (1) · Inflammatory Bowel Diseases (1) · Ischemia (1) · Ischemic Attack, Transient (1) · Ischemic Stroke (1) · Malaria (1)
GlaxoSmithKline (3) · Chipscreen Biosciences, Ltd. (2) · Oscotec Inc. (2) · AQILION AB (1) · Allergan (1) · Amicus Therapeutics (1) · Andrew Slivka (1) · Angela Stockton (1) · Chong Kun Dang Pharmaceutical (1) · Columbia University (1) · Ferring Pharmaceuticals (1) · Gadjah Mada University (1) · Jiangxi Kvvit Pharmaceutical Co., Ltd. (1) · Jinling Hospital, China (1) · Massachusetts General Hospital (1)
United States (16) · United Kingdom (5) · China (4) · Australia (1) · Canada (1) · Germany (1) · India (1) · Indonesia (1)
Angela Paliaologou-Gallis, DDS (1) · Aquilur Rahman, PhD (1) · Charles H. Pierce, MD, PhD (1) · Christine A Rabinak, PhD (1) · Dr Deven Parmar, MD (1) · Elizabeth Shane, MD (1) · Emad Aldujaili (1) · Gary N Asher, MD, MPH (1) · Janet E Hall, MD (1) · Joanne Marjason (1)
PMID 22458601, PMID 22917853, PMID 27536442, PMID 28800383, PMID 29226626, PMID 31900292, PMID 33165774, PMID 41270825
2017 (1), R01AG013241 (1), R01AI065200 (1), R43MH082461 (1), R61MH111935 (1)